生长抑素联合复方丹参注射液治疗急性胰腺炎疗效的Meta分析

目的:评价生长抑素联合复方丹参注射液与单用生长抑素治疗急性胰腺炎的疗效。方法:通过Cochrane图书馆、Medline数据库、EMbase数据库、CNKI数据库、维普数据库以及万方数据库,检索单用生长抑素(对照组)及联合应用生长抑素和复方丹参注射液(实验组)治疗急性胰腺炎的临床随机对照(RCT)研究文献,按照Cochrane指南进行相关研究的筛选与纳入,使用RevMan 5.1软件进行偏倚风险判断和Meta分析,使用Grade软件进行证据系统推荐分级,比较对照组和实验组总有效率、并发症发生率及病死率的差异。结果:共纳入RCT研究文献10篇,总体偏倚风险一般,Grade系统推荐分级中等。相比于对照组,实验组总有效率较高[RR=1.17,95%CI:(1.08-1.26),P0.05],并发症发生率较低[RR=0.44,95%CI:(0.30-0.64),P0.05],病死率较低[RR=0.36,95%CI:(0.17-0.75),P0.05]。结论:生长抑素联合复方丹参注射液治疗急性胰腺炎比单用生长抑素疗效更好,安全性更高。

Meta Analysis of Somatostatin Combined with Compound Salvia Miltiorrhiza on Treatment of Acute Pancreatitis

Objective：Systematically evaluate the curative effect of somatostatin combined compound salvia miltiorrhiza inj ection and somatostatin alone as a treatment of acute pancreatitis.Method：The Cochrane library,the Medline database,the EMBASE database,the CNKI database,the VIP database and the Wanfang database were searched for the clinical randomized controlled trail investigating somatostatin combined compound salvia miltiorrhiza inj ection for the treatment of acute pancreatitis.Then j udged the studies according to the Cochrane criteria and Grad profiler.A meta-analysis was conducted by the RevMan 5 .1 software.Results：Ten clinical trials were included. The risk of bias of those studies were not up to the mark,and the quality of those trials which was analyzed by Grade were between moderate to very low.Compared with somatostatin alone group,drug application group has a higher total effective rate [RR=1.17,95%CI：（1.08-1.26）,P〈0.05],a lower incidence of complications [RR=0.44,95%CI：（0.30-0.64）,P〈0.05],a lower mortality [RR=0.36,95%CI：（0.17-0.75）,P〈0.05].Conclu-sion：Somatostatin combined compound salvia miltiorrhiza inj ection,as a treatment of acute pancreatitis,has a better curative effect and a more reliable drug safety when compared with the treatment of using somatostatin alone.